Stemline Therapeutics Company Profile (NASDAQ:STML)

About Stemline Therapeutics

Stemline Therapeutics logoStemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: STML
  • CUSIP:
Key Metrics:
  • Previous Close: $8.70
  • 50 Day Moving Average: $7.40
  • 200 Day Moving Average: $6.19
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.37
  • P/E Growth: 0.00
  • Market Cap: $155.08M
  • Outstanding Shares: 17,825,000
  • Beta: 0.23
Additional Links:
Companies Related to Stemline Therapeutics:

Analyst Ratings

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.33 (168.20% upside)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetDetails
8/25/2016Roth CapitalReiterated RatingBuy$32.00View Rating Details
8/23/2016WedbushReiterated RatingOutperform$15.00View Rating Details
8/5/2016Jefferies GroupReiterated RatingBuyView Rating Details
3/18/2016Rodman & RenshawReiterated RatingBuyView Rating Details
3/15/2016Cowen and CompanyReiterated RatingOutperformView Rating Details
4/27/2015HC WainwrightInitiated CoverageBuy$38.00View Rating Details
(Data available from 8/29/2014 forward)

Earnings

Earnings History for Stemline Therapeutics (NASDAQ:STML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016        
8/4/2016($0.55)($0.52)ViewN/AView Earnings Details
5/9/2016Q116($0.59)($0.51)$121.43 million$205.65 millionViewN/AView Earnings Details
3/14/2016Q4($0.57)($0.58)ViewN/AView Earnings Details
11/6/2015Q315($0.59)($0.53)ViewN/AView Earnings Details
8/10/2015Q2($0.41)($0.58)ViewN/AView Earnings Details
5/11/2015Q1($0.45)($0.46)ViewN/AView Earnings Details
3/13/2015($0.60)($0.53)ViewN/AView Earnings Details
11/12/2014Q314($0.58)($0.53)ViewN/AView Earnings Details
8/14/2014($0.71)($0.47)ViewN/AView Earnings Details
5/22/2014($0.72)($0.70)$0.07 million$0.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stemline Therapeutics (NASDAQ:STML)
Current Year EPS Consensus Estimate: $-2.11 EPS
Next Year EPS Consensus Estimate: $-1.99 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.59)($0.55)($0.57)
Q2 20163($0.56)($0.49)($0.53)
Q3 20163($0.61)($0.52)($0.56)
Q4 20163($0.67)($0.54)($0.59)
Q1 20171($0.55)($0.55)($0.55)
Q2 20171($0.41)($0.41)($0.41)
Q3 20171($0.38)($0.38)($0.38)
Q4 20171($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stemline Therapeutics (NASDAQ:STML)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Stemline Therapeutics (NASDAQ:STML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/8/2016David GioncoCAOSell1,148$5.32$6,107.36View SEC Filing  
3/8/2016Ivan BergsteinCEOSell5,537$5.34$29,567.58View SEC Filing  
3/8/2016Kenneth HobermanCOOSell2,412$5.34$12,880.08View SEC Filing  
2/17/2016Ivan BergsteinCEOSell3,244$4.46$14,468.24View SEC Filing  
2/17/2016Kenneth HobermanCOOSell1,503$4.54$6,823.62View SEC Filing  
1/20/2016David GioncoCAOSell3,217$4.82$15,505.94View SEC Filing  
11/30/2015Ivan BergsteinCEOSell12,235$8.20$100,327.00View SEC Filing  
4/27/2015Eric K RowinskyInsiderSell10,824$15.77$170,694.48View SEC Filing  
3/19/2015Kenneth HobermanCOOSell17,307$16.43$284,354.01View SEC Filing  
1/20/2015David GioncoCAOSell3,311$14.22$47,082.42View SEC Filing  
11/26/2014Ivan BergsteinCEOSell11,974$14.40$172,425.60View SEC Filing  
9/3/2014Ivan BergsteinCEOBuy2,000$11.05$22,100.00View SEC Filing  
9/2/2014Kenneth HobermanCOOBuy2,000$10.99$21,980.00View SEC Filing  
9/2/2014Kenneth J ZuerblisDirectorBuy1,000$11.14$11,140.00View SEC Filing  
5/30/2013Kenneth J ZuerblisDirectorBuy3,000$16.01$48,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Stemline Therapeutics (NASDAQ:STML)
DateHeadline
4-traders.com logoStemline Therapeutics : Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401 (NASDAQ:STML)
www.4-traders.com - August 24 at 10:43 AM
News IconShares Going Higher in Session: Stemline Therapeutics, Inc. (NASDAQ:STML) - Post News (NASDAQ:STML)
www.kentuckypostnews.com - August 23 at 7:46 PM
News IconShares Seen Gapping Up Pre-Market: Stemline Therapeutics, Inc. (NASDAQ:STML) - Post News (NASDAQ:STML)
www.kentuckypostnews.com - August 23 at 7:46 PM
streetinsider.com logoStemline Therapeutics' (STML) SL-401 Receives FDA Breakthrough Therapy Designation as BPDCN Treatment - StreetInsider.com (NASDAQ:STML)
www.streetinsider.com - August 23 at 7:46 PM
streetinsider.com logoStemline Therapeutics' (STML) SL-401 Receives FDA Breakthrough Therapy Designation as BPDCN Treatment (NASDAQ:STML)
www.streetinsider.com - August 23 at 12:08 PM
publicnow.com logoStemline Therapeutics Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for SL-401 (NASDAQ:STML)
www.publicnow.com - August 23 at 12:08 PM
feeds.reuters.com logoBRIEF-Stemline Therapeutics expect to provide further updates around multiple SL-401 (NASDAQ:STML)
feeds.reuters.com - August 23 at 7:57 AM
News IconEarnings & Estimates for Stemline Therapeutics, Inc. (NASDAQ:STML) - Post News (NASDAQ:STML)
www.kentuckypostnews.com - August 20 at 11:33 AM
News IconStemline Therapeutics, Inc. (NASDAQ:STML) Shares in Focus According to the Crowd & Analysts - Post News (NASDAQ:STML)
www.kentuckypostnews.com - August 20 at 11:33 AM
finance.yahoo.com logoSTEMLINE THERAPEUTICS INC Financials (NASDAQ:STML)
finance.yahoo.com - August 17 at 7:56 PM
finance.yahoo.com logoStemline Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:STML)
finance.yahoo.com - August 11 at 10:55 AM
equities.com logoStemline Therapeutics Inc. (STML) is Trading Higher on Unusual Volume for August 08 - Equities.com (NASDAQ:STML)
www.equities.com - August 10 at 10:46 AM
biz.yahoo.com logoSTEMLINE THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:STML)
biz.yahoo.com - August 8 at 7:51 PM
biz.yahoo.com logoSTEMLINE THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:STML)
biz.yahoo.com - August 4 at 8:03 PM
nasdaq.com logoStemline Therapeutics Reports Second Quarter 2016 Financial Results and Highlights Recent Clinical Progress (NASDAQ:STML)
m.nasdaq.com - August 4 at 10:50 AM
sg.finance.yahoo.com logoStemline Therapeutics reports 2Q loss (NASDAQ:STML)
sg.finance.yahoo.com - August 4 at 10:50 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Stemline Therapeutics, Inc. (NASDAQ:STML) - TGP (NASDAQ:STML)
telanaganapress.com - July 22 at 7:26 PM
News IconToday Stemline Therapeutics Inc Stock Rises - Consumer Eagle (NASDAQ:STML)
www.consumereagle.com - July 20 at 10:33 AM
News IconStemline Therapeutics, Inc. (NASDAQ:STML): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:STML)
www.engelwooddaily.com - July 20 at 10:33 AM
News IconTrading Performance and Target Watch for Stemline Therapeutics, Inc. (NASDAQ:STML) - Press Telegraph (NASDAQ:STML)
presstelegraph.com - July 19 at 8:36 AM
News IconIncreased Volatility Noted on Shares of: Stemline Therapeutics, Inc. (NASDAQ:STML) - Engelwood Daily (NASDAQ:STML)
www.engelwooddaily.com - July 16 at 10:47 AM
news.cmlviz.com logoStemline Therapeutics Inc Upside Stock Momentum at Extreme Strength - CML News (NASDAQ:STML)
news.cmlviz.com - July 15 at 12:52 PM
News IconAnalyst Target and Average Rating Watch: Stemline Therapeutics, Inc. (NASDAQ:STML) - Press Telegraph (NASDAQ:STML)
presstelegraph.com - July 14 at 11:12 AM
fiscalstandard.com logoBroker Outlook For Stemline Therapeutics, Inc. (STML) - Fiscal Standard (NASDAQ:STML)
www.fiscalstandard.com - July 14 at 11:12 AM
ftsenews.co.uk logoNew Broker Ratings For Stemline Therapeutics, Inc. (STML) - FTSE News (NASDAQ:STML)
www.ftsenews.co.uk - July 12 at 7:51 PM
News IconStemline Therapeutics, Inc. (NASDAQ:STML) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:STML)
www.engelwooddaily.com - July 12 at 7:51 PM
News IconStemline Therapeutics Inc (NASDAQ:STML) Institutional Investors Quarterly Sentiment - Consumer Eagle (NASDAQ:STML)
www.consumereagle.com - July 11 at 7:33 PM
News IconStemline Therapeutics Incorporated (NASDAQ:STML) Short Interest Decreased By 13.29% - Press Telegraph (NASDAQ:STML)
presstelegraph.com - July 8 at 7:35 PM
news.cmlviz.com logoStemline Therapeutics, Inc. Stock Momentum Hits Strength - CML News (NASDAQ:STML)
news.cmlviz.com - July 8 at 7:35 PM
News IconShare Performance Recap for: Stemline Therapeutics, Inc. (NASDAQ:STML) - Press Telegraph (NASDAQ:STML)
presstelegraph.com - July 5 at 11:28 AM
fiscalstandard.com logoBroker Outlook For The Week Ahead Stemline Therapeutics, Inc. (STML) - Fiscal Standard (NASDAQ:STML)
www.fiscalstandard.com - July 5 at 11:28 AM
News IconStemline Therapeutics Incorporated (NASDAQ:STML) Shorted Shares Decreased By 13.29% - Press Telegraph (NASDAQ:STML)
presstelegraph.com - July 4 at 11:17 AM
fiscalstandard.com logoStemline Therapeutics, Inc. (STML) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:STML)
www.fiscalstandard.com - June 28 at 7:29 PM
news.cmlviz.com logoStemline Therapeutics, Inc. (NasdaqCM:STML) Stock Momentum Hits Strength - CML News (NASDAQ:STML)
news.cmlviz.com - June 22 at 7:33 PM
fiscalstandard.com logoRecently Issued Stock Ratings For Stemline Therapeutics, Inc. (STML) - Fiscal Standard (NASDAQ:STML)
www.fiscalstandard.com - June 17 at 7:19 PM
live-pr.com logoStemline Therapeutics, Inc. (STML) - Financial and Strategic SWOT Analysis Review - New Market Study Published (NASDAQ:STML)
www.live-pr.com - June 16 at 12:00 PM
equities.com logoStemline Therapeutics Inc. (STML) Drops 7.81% on June 09 - Equities.com (NASDAQ:STML)
www.equities.com - June 11 at 10:34 AM
streetinsider.com logoStemline Therapeutics (STML) Announces SL-401 Phase 2 BPDCN Trial Results to be Presented at EHA (NASDAQ:STML)
www.streetinsider.com - June 10 at 7:58 PM
finance.yahoo.com logoStemline Therapeutics’ SL-401 Phase 2 BPDCN Trial Results to be Delivered Via Oral Presentation at the EHA Meeting this Weekend (NASDAQ:STML)
finance.yahoo.com - June 10 at 7:58 PM
publicnow.com logoStemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results to be Delivered Via Oral Presentation at the EHA Meeting this Weekend (NASDAQ:STML)
www.publicnow.com - June 10 at 12:09 PM
equities.com logoStemline Therapeutics Inc. (STML) is Trading Lower on Unusual Volume for June 06 - Equities.com (NASDAQ:STML)
www.equities.com - June 8 at 10:44 AM
biz.yahoo.com logoSTEMLINE THERAPEUTICS INC Files SEC form 8-K, Other Events (NASDAQ:STML)
biz.yahoo.com - June 6 at 4:32 PM
investornewswire.com logoCan Stemline Therapeutics, Inc. (NASDAQ:STML) Keep Up with Analyst Expectations? - Investor Newswire (NASDAQ:STML)
www.investornewswire.com - June 6 at 11:39 AM
publicnow.com logoStemline Therapeutics to Present at the Jefferies 2016 Healthcare Conference; Will Feature Highlights from this Past Weekend's Oral Presentation of SL-401 Phase 2 Results in BPDCN at ASCO (NASDAQ:STML)
www.publicnow.com - June 6 at 7:58 AM
finance.yahoo.com logoStemline Therapeutics to Present at the Jefferies 2016 Healthcare Conference; Will Feature Highlights from this Past Weekend’s Oral Presentation of SL-401 Phase 2 Results in BPDCN at ASCO (NASDAQ:STML)
finance.yahoo.com - June 6 at 7:30 AM
finance.yahoo.com logo9:02 pm Stemline Therapeutics presents Phase 2 data for SL-401 demonstrating 89% overall response rate in BPDCN (NASDAQ:STML)
finance.yahoo.com - June 5 at 9:02 PM
publicnow.com logoStemline Therapeutics' SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds (NASDAQ:STML)
www.publicnow.com - June 4 at 7:18 PM
finance.yahoo.com logoStemline Therapeutics’ SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASCO; High Response Rates Demonstrated Across All Lines As Enrollment Proceeds (NASDAQ:STML)
finance.yahoo.com - June 4 at 7:07 PM
publicnow.com logoStemline Therapeutics' SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow (NASDAQ:STML)
www.publicnow.com - June 3 at 7:15 AM
finance.yahoo.com logoStemline Therapeutics’ SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow (NASDAQ:STML)
finance.yahoo.com - June 3 at 7:07 AM

Social

Stemline Therapeutics (NASDAQ:STML) Chart for Monday, August, 29, 2016


Last Updated on 8/29/2016 by MarketBeat.com Staff